Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Octoplus  /  Medicines Company -MDCO 216 (ApoA-I Milano)

Ontvang nu dagelijks onze kooptips!

word abonnee

Octoplus« Terug naar discussie overzicht

Medicines Company -MDCO 216 (ApoA-I Milano)

26 Posts
Pagina: «« 1 2 | Laatste | Omlaag ↓
  1. [verwijderd] 10 februari 2012 08:47
    samenvoegen....

    [Posted 02/09/2012]

    ISSUE: FDA notified healthcare professionals and patients that drug interactions between the hepatitis C virus (HCV) protease inhibitor Victrelis (boceprevir) and certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these medicines when they are used together.

    A drug interaction study showed that taking boceprevir (Victrelis) with ritonavir (Norvir) in combination with atazanavir (Reyataz) or darunavir (Prezista), or with Kaletra (lopinavir/ritonavir) reduced the blood levels of the HIV medicines and boceprevir in the body (see Data Summary below). FDA will be updating the Victrelis drug label to include information about these drug interactions.

    BACKGROUND: Victrelis is a hepatitis C virus (HCV) protease inhibitor used with the medicines pegiBACKGROUND: Victrelis is a hepatitis C virus (HCV) protease inhibitor used with the medicines peginterferon alfa and ribavirin to treat chronic (long-lasting) hepatitis C infection in adults. HIV protease inhibitors are a class of anti-viral drugs used to treat HIV infection. Ritonavir is an HIV protease inhibitor used to “boost” other HIV protease inhibitors, increasing their levels in the blood and making them more effective.

    RECOMMENDATION: Patients should not stop taking any of their medicines without talking to their healthcare professional. Patients should contact their healthcare professional if they have any questions or concerns.

    Healthcare professionals who have started patients infected with both chronic HCV and HIV on Victrelis and antiretroviral therapy containing a ritonavir-boosted protease inhibitor should closely monitor patients for HCV treatment response and for potential HCV and HIV virologic rebound.

    Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
    nterferon alfa and ribavirin to treat chronic (long-lasting) hepatitis C infection in adults. HIV protease inhibitors are a class of anti-viral drugs used to treat HIV infection. Ritonavir is an HIV protease inhibitor used to “boost” other HIV protease inhibitors, increasing their levels in the blood and making them more effective.
  2. patient 5 oktober 2012 13:31
    MDCO-216 (formerly referred to as apoA-I Milano): MDCO-216 is a naturally occurring variant of a
    protein found in human high-density lipoprotein (HDL) that has the potential to reverse atherosclerotic
    plaque development and reduce the risk of coronary events in patients with ACS. The company
    exclusively licensed MDCO-216 from Pfizer Inc. in December 2009. As per the terms of the agreement,
    Pfizer received an up-front payment of $10 million and will receive additional payments upon the
    achievement of certain clinical, regulatory, and sales milestones up to a total of $410 million. Pfizer will
    also be eligible to receive single-digit royalty payments on worldwide net sales of MDCO-216. The
    company received the transfer of technology and know-how from Pfizer in 2Q10. The company expects
    to submit an IND and commence a phase I study in 2H12.

    www.zacks.com/ZER/rd_get_pdf.php?r=MDCO
  5. forum rang 7 wiegveld 2 september 2019 19:50
    Na enkele dagen licht dalende koers en vandaag Wall Street op slot wordt vanavond de inclirisan studie gepresenteerd.

    54% daling slecht cholesterol met halfjaarlijkse toediening en niet meer bijwerkingen dan placebo. Klinkt te mooi om waar te zijn. Slecht nieuws voor Amgen en Sanofi met hun PCKS 9 remmers. Morgen verwacht ik daling van die twee en forse stijging van dit bedrijf.

    www.themedicinescompany.com/investor/...
26 Posts
Pagina: «« 1 2 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 860,01 -0,62%
EUR/USD 1,0653 +0,09%
FTSE 100 7.895,85 +0,24%
Germany40^ 17.720,70 -0,65%
Gold spot 2.393,97 +0,61%
NY-Nasdaq Composite 15.601,50 -0,52%

Stijgers

WDP
+3,12%
Kendrion
+2,92%
EBUSCO...
+2,67%
Vopak
+2,61%
NX FIL...
+2,17%

Dalers

JUST E...
-5,11%
TomTom
-4,68%
Fugro
-4,30%
ASMI
-4,00%
BESI
-3,64%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!